Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018

Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the Company is supporting an educational satellite symposium on: “Chlormethine gel: new treatment option for all stages of MF-CTCL” at the forthcoming European Association of Dermato Oncology (EADO) Congress in Barcelona, Spain.

The symposium will take place on Wednesday 7 November, 12:45 – 13:45 at the Auditorium, Palau de Congressos de Catalunya, Barcelona, Spain.

This educational event will bring together a panel of leading experts in the treatment of Cutaneous Lymphoma, to provide an update on Ledaga®, a current treatment option for Mycosis Fungoides Cutaneous T-cell lymphoma (MF-CTCL).

The event will outline the current landscape of MF-CTCL treatment and will provide with a better understanding of how Ledaga ® will fit in the scenario of the treatment options in this rare disease. Patient cases in different stages of MF-CTCL will be discussed. The full programme for the event is below.

Sergio Cantoreggi, Chief Scientific Officer at the Helsinn Group, commented: “We are delighted to support the 14th EADO Congress. The presenters at this symposium are leaders in the field of research into CTCL and will provide a high-quality overview of the breadth of MF-CTCL treatment approaches and improving treatments options for patients living with this disease. Helsinn is committed to improving the quality of life and well-being of patients with CTCL and other types of cancer.”

Julia J. Scarisbrick, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, said: “Half of CTCL patients are diagnosed with MF-CTCL, and there is no cure for this rare disease. It is important to explore future treatment options and this symposium will encourage a wider discussion on the evolving treatment options for patients living with MF-CTCL. We are pleased to have the support of Helsinn in bringing together this expert panel at the 14th EADO congress, and look forward to a lively and productive discussion.”
Programme

12:45–12:50  **Opening and welcome**  
Julia J. Scarisbrick (UK)

12:50–13:05  **Introduction to MF-CTCL treatment: guidelines and options**  
Martine Bagot (France)

13:05–13:20  **Ledaga®: a topical treatment strategy for all stages of MF-CTCL**  
Julia J. Scarisbrick (UK)

13:20–13:30  **Incorporating topical chlormethine gel into the current MF-CTCL treatment landscape**  
Martine Bagot (France)

13:30–13:40  **Cutaneous reactions to chlormethine gel: interpretation and management**  
Julia J. Scarisbrick (UK)

13:40–13:45  **Closing remarks**  
Julia J. Scarisbrick (UK)

END

About Mycosis Fungoides

Mycosis fungoides (MF) accounts for almost 60% of all primary cutaneous T-cell lymphomas, a form of non-Hodgkin's lymphoma. The cause of MF remains unknown and there are no curative treatments. MF has an indolent clinical course, slowly progressing from patches to thicker plaques and eventually to tumours over years or decades. Signs include rash, patch and plaques with severe itch. MF typically affects older adults (median age at diagnosis: 55-60 years) with male predominance. However, people of all ages can be affected. Depending on the stage and diagnosis at presentation, life expectancy can vary from less than five years after diagnosis to full life expectancy. Evidence from seven global studies (US, n = 4; Europe, n = 3) indicated that the incidence of CTCL has increased over time, reaching ∼10 cases per million individuals per year.

About Ledaga®

Ledaga® gel is an alkylating drug indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients. Ledaga® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for
MF-CTCL patients in all stages) and received Orphan Drug Designation. It will be commercially available upon completion of Post Authorisation Measures. In France it is provided through an “Autorisation Temporaire d’Utilisation (ATU) de cohort”.

For additional information please see the EU Summary of Product Characteristics.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

For more information:

Helsinn Group Media Contact

Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo.